180 Life Sciences Corp.
ATNF
$1.07
-$0.01-0.93%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 92.28% | 75.71% | 63.95% | 48.52% | -153.64% |
| Total Depreciation and Amortization | -30.24% | 7.29% | 3.07% | -3.02% | 36.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -97.62% | -77.78% | -69.95% | -62.46% | 995.91% |
| Change in Net Operating Assets | -107.32% | -89.52% | -127.10% | -100.52% | 617.20% |
| Cash from Operations | 76.99% | 68.60% | 41.93% | 9.94% | 17.85% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -8.63% | -8.63% | -8.63% | -8.63% | -34.45% |
| Total Debt Repaid | -9.67% | 23.77% | 35.30% | 24.81% | 25.36% |
| Issuance of Common Stock | -93.07% | -75.28% | -45.35% | -45.35% | 84.62% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 94.36% | 72.60% | 37.46% | 37.46% | -100.00% |
| Cash from Financing | -95.73% | -75.60% | -44.01% | -45.67% | 79.78% |
| Foreign Exchange rate Adjustments | -232.46% | -139.08% | 112.64% | 5,100.00% | -170.77% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -166.45% | -324.91% | 34.82% | -298.14% | 88.57% |
